An integrated view of the activities of defibrotide
- PMID: 8807733
An integrated view of the activities of defibrotide
Abstract
Defibrotide is a polydeoxyribonucleotide sodium salt extracted from mammalian organs. Its mean molecular weight is 15,000-30,000 daltons. Defibrotide contains aptamers, i.e., single-stranded polynucleotides with a well-defined base sequence and composition (5'-GGTTGG-ATT-GGTTGG-3' and 5'-GGTTGG-ATC-GGTTGG-3') that bind thrombin. For the time being, these aptamers are the only ones that have been identified in defibrotide, but there may also be other aptamers that bind proteins other than thrombin. Defibrotide has no anticoagulant activity, but in some other aspects it probably parallels heparin. Heparin is a sulfated polysaccharide sodium salt with a mean molecular weight ranging from 5,000 to 40,000 daltons extracted from mammalian organs. It contains disaccharide sequences of well-defined structure and frequency. Heparin binds an array of proteins, enzymes, and growth factors and shows inhibitory or stimulatory or protective activity. Defibrotide has a spectrum of interesting pharmacological properties that make this drug very useful for the treatment of arterial and venous thrombotic diseases. In fact, defibrotide has profibrinolytic, antithrombotic-thrombolytic, anti-ischemic, and antiatherosclerotic activity and protective activity in shock. What have all the above activities to do with a single drug? The explanation is that atherosclerosis, myocardial, renal, and liver ischemia, hemorrhagic and septic shock, and shock induced by occlusion of splanchnic artery and thrombosis are different facets of the same entity: the polyhedric inflammatory process.
Similar articles
-
Defibrotide: properties and clinical use of an old/new drug.Vascul Pharmacol. 2013 Jul-Aug;59(1-2):1-10. doi: 10.1016/j.vph.2013.05.001. Epub 2013 May 14. Vascul Pharmacol. 2013. PMID: 23680861 Review.
-
Fibrinolytic effects of defibrotide in atherosclerotic patients.Semin Thromb Hemost. 1991;17 Suppl 1:101-5. Semin Thromb Hemost. 1991. PMID: 2068562
-
Absorption through the peritoneum of the macromolecular profibrinolytic drug defibrotide in the rabbit.Semin Thromb Hemost. 1991 Oct;17(4):404-6. doi: 10.1055/s-2007-1002644. Semin Thromb Hemost. 1991. PMID: 1803509
-
Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.Drugs. 1993 Feb;45(2):259-94. doi: 10.2165/00003495-199345020-00007. Drugs. 1993. PMID: 7681375 Review.
-
Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(1-2):177-80. Folia Haematol Int Mag Klin Morphol Blutforsch. 1988. PMID: 2459016 Review.
Cited by
-
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.Clin Cancer Res. 2009 Feb 15;15(4):1210-21. doi: 10.1158/1078-0432.CCR-08-1270. Clin Cancer Res. 2009. PMID: 19228727 Free PMC article.
-
Thrombotic microangiopathy in haematopoietic cell transplantation: an update.Mediterr J Hematol Infect Dis. 2010;2(3):e2010033. doi: 10.4084/MJHID.2010.033. Epub 2010 Nov 3. Mediterr J Hematol Infect Dis. 2010. PMID: 21776339 Free PMC article.
-
Translational research efforts in biomarkers and biology of early transplant-related complications.Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S101-8. doi: 10.1016/j.bbmt.2010.11.025. Biol Blood Marrow Transplant. 2011. PMID: 21195297 Free PMC article. Review.
-
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?Biomedicines. 2021 Feb 1;9(2):132. doi: 10.3390/biomedicines9020132. Biomedicines. 2021. PMID: 33535377 Free PMC article. Review.
-
Effective DNA inhibitors of cathepsin g by in vitro selection.Int J Mol Sci. 2008 Jun;9(6):1008-1023. doi: 10.3390/ijms9061008. Epub 2008 Jun 20. Int J Mol Sci. 2008. PMID: 19325843 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials